Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes

References

• Ogata K, Nakamura K, Yokose N, Tachibana M, Taniguchi O, Iwakiri R, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887–3896
   PubMed Web of Science ®Google Scholar
• Aul C, Bowen D T, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71–86
   PubMed Web of Science ®Google Scholar
• Howe R B, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E. The WHO does make a difference. Blood 2004; 103: 3265–3270
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Arthur D C, Jabbour N, Xie X Y, Molldrem J, Barrett A J, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979–987
   PubMed Web of Science ®Google Scholar
• Kussick S J, Fromm J R, Rossini A, Li Y, Chang A, Norwood T H, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation of myelodysplasia. Am J Clin Pathol 2005; 124: 170–181
   PubMed Web of Science ®Google Scholar
• Orfao A, Ortuno F, De Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004; 58A: 62–71
   Web of Science ®Google Scholar
• Lorand-Metze I, Ribeiro E, Lima C SP, Batista L S, Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007; 31: 147–155
   PubMed Web of Science ®Google Scholar
• Vardiman J W. Myelodysplasic syndromes, chronic myeloproliferative diseases and myelodysplastic/myeloproliferative diseases. Semin Pathol 2003; 20: 154–179
   PubMed Web of Science ®Google Scholar
• Valent P, Horny H P, Bennett J M, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727–736
   PubMed Web of Science ®Google Scholar
• NCCN guidelines for treatment of myelodysplastic syndromes -v.1.2009 (NCCN Clinical Practice Guidelines in Oncology™, accessed December 12, 2008, at www.nccn.org)
   Google Scholar
• Van de Loosdrecht A, Westers T, Westra A, Drager A, Van der Velden V, Ossenkoppele G. Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067–1077
   PubMed Web of Science ®Google Scholar
• Kussick S J, Wood B L. Using 4-color flow cytometry to identify abnormal myeloid populations. Am J Clin Pathol 2003; 120: 854–865
   PubMed Web of Science ®Google Scholar
• Kussick S J, Wood B L. Four-color cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Arch Pathol Lab Med 2003; 127: 1140–1147
   PubMed Web of Science ®Google Scholar
• Elghetany M T. Surface marker abnormalities in myelodysplastic syndromes. Hematologica 1998; 83: 1104–1115
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta M G, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow Cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndromes. Leukemia 2005; 19: 776–783
   PubMed Web of Science ®Google Scholar
• Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349–2356
   PubMed Web of Science ®Google Scholar
• Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cell modules an neutrophil in myelodysplastic syndromes. Br J Haematol 1997; 98: 108–113
   PubMed Web of Science ®Google Scholar
• Karmon Y, Manaster J, Chezar J. Immunophenotyping characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis. Cytometry B Clin Cytometry 2002; 50: 225–230
   Web of Science ®Google Scholar
• Wells D A, Benesch M, Loken M R, Vallejo C, Myerson D, Leisenring W M, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394–403
   PubMed Web of Science ®Google Scholar
• Bowen K L, Davis B H. Abnormal patterns of expression of CD16 (Fcr-III) and CD11b (CRIII) in the bone marrow of patients with myelodysplastic syndromes. Lab Hematol 1997; 3: 292–298
   Google Scholar
• Xu D, Schultz C, Akker Y, Cannizzaro L, Ramesh K H, Du J, et al. Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. Am J Hematol 2003; 74: 9–16
   PubMed Web of Science ®Google Scholar
• Benesch M, Deeg H J, Wells D, Loken M. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 2004; 9: 171–177
   PubMedGoogle Scholar
• Torsten H, Wolfgang K. Classification and staging of myelodysplastic syndromes. Hematologic Malignancies: Myelodysplastic Syndromes, H J Deeg, D T Bowen, S D Gore, T Haferlach, M M Le Beau, C Niemeyer. Springer, Berlin Heidelberg 2007; 39–53
   Google Scholar
• Cherian S, Moore J, Bantly A, Vergilio J A, Klein P, Luger S, et al. Peripheral Blood MDS Score: A new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005; 64: 9–17
   PubMed Web of Science ®Google Scholar
• Del Canizo C M, Fernandez E, Lopez A, Vidriales B, Villaron E, Arroyo J L, et al. Immunophenotypic analysis of myelodysplastic syndromes. Hematologica 2003; 88: 402–407
   PubMed Web of Science ®Google Scholar
• Elghetany M T, Patel J, Martinez J, Schwab H. CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. Cytometry B Clin Cytom 2003; 51: 9–13
   PubMed Web of Science ®Google Scholar
• Elghetany M T, Ge Y, Patel J, Martinez J, Uhrova H. Flow cytometric study of neutrophil granulopoiesis in normal bone marrow using an expanded panel of antibodies: correlation with morphologic assessments. J Clin Lab Anal 2004; 18: 36–41
   PubMed Web of Science ®Google Scholar
• Pagnucco G, Giambanco C, Gervasi F. The role of flow cytometric immunophenotyping in myelodysplastic syndromes. Ann NY Acad Sci 2006; 1089: 383–394
   PubMed Web of Science ®Google Scholar
• Terstappen L WMM, Loken M R. Myeloid differentiation in normal bone marrow and acute leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2: 229–240
   PubMed Web of Science ®Google Scholar
• Terstappen L WMM, Safford M, Loken M R. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990; 4: 657–663
   PubMed Web of Science ®Google Scholar
• Elghetany M T. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 2002; 28: 260–274
   PubMed Web of Science ®Google Scholar
• Elghetany M T, Peterson B, MacCallum J, Nelson D A, Varney J F, Sullivan A K, et al. Deficiency of neutrophil granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 studied by the cancer and leukemia group B. Leuk Res 1997; 21: 801–806
   PubMed Web of Science ®Google Scholar